Prostate-specific antigen

Seminars in Cancer Biology

Volumn 9, Issue 2, 1999, Pages 83-93

  Stenman, Ulf Håkan ^a   Leinonen, Jari ^a   Zhang, Wan Ming ^a   Finne, Patrik ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; SERINE PROTEINASE;

ARTIFICIAL NEURAL NETWORK; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EJACULATION; HUMAN; MALE; PHYSICAL EXAMINATION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REGRESSION ANALYSIS; REVIEW; SEMINAL PLASMA; STATISTICAL ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0032992920     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0086     Document Type: Article

References (93)

1. Wingo PA, Landis S, Ries LA. An adjustment to the 1997 estimate for new prostate cancer cases. Cancer. 80:1997;1810-1813.
2. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli E. Isolation, characterization and amino acid sequence of g-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem. 170:1987;110-120.
3. Lundwall Å, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 214:1987;317-322.
4. Henttu P, Viliko P. cDNA coding for the entire prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Comm. 160:1989;903-910.
5. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate. 2:1981;89-96.
6. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 76:1985;1899-1903.
7. Zhang W-M, Leinonen J, Kalkkinen N, Dowell B, Stenman U-H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 41:1995;1567-1573.
8. Espana F, Sanchez CJ, Vera CD, Estelles A, Gilabert J. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med. 122:1993;711-719.
9. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 75:1992;1046-1053.
10. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun. 192:1993;940-947.
11. Yoshida E, Ohmura S, Sugiki M, Maruyama M, Mihara H. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer. 63:1995;863-865.
12. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 12:1988;39-46.
13. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol. 151:1994;1558-1564.
14. Kamoshida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol. 21:1990;1108-1111.
15. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am. 24:1997;275-282.
16. Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein E, Diamandis EP. The periurethral glands do not significantly influence the serum prostate specific antigen concentration [see comments]. J Urol. 155:1996;1658-1660.
17. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
18. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 145:1991;907-923.
19. Stenman UH. Prostate-specific antigen, clinical use and staging: an overview. Br J Urol. 79:1997;1-3.
20. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
21. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
22. Leinonen J, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol. 155:1996;1099-1103.
23. Zhang W-M, Leinonen J, Stenman U-H. Prostate specific antigen (PSA) complexes with and cleaves a1-protease inhibitor in vitro. J Urol. 155:1996;626A.
24. Stenman U-H, Leinonen J, Zhang W-M, Finne P, Wu P. The clinical importance of free PSA. Curr Opin Urol. (in press):1998;53-60.
25. Björk T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, Lilja H. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology. 51:1998;57-62.
26. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 50:1997;710-714.
27. Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol. 158:1997;1606-1609.
28. Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol. 157:1997;2166-2170.
29. Bjartell A, Björk G, Matikainen M-T, Abrahamsson P, diSant'Angese A, Lilja H. Production of alpha-1-antichymotrypsin by PSA-containing cells of the human prostatic epithelium. Urology. 42:1994;502-510.
30. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA. 83:1986;3166-3170.
31. Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem. 41:1995;1480-1488.
32. Stenman U-H, Leinonen J, Zhang W-M. Standardization of PSA determinations. Scand J Clin Lab Invest. 55:1995;221-225.
33. Leinonen J, Lovgren T, Vornanen T, Stenman UH. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem. 39:1993;2098-2103.
34. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
35. Woodrum. DL, French CM, Hill TM, Roman SJ, Slatore HL, Shaffer JL. Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem. 43:1997;1203-1208.
36. Lilja H, Björk T, Abrahamsson P-A, Stemnan U-H, Shaw N, Dowell B. Improved separation between normals, benign prostatic hyperplasia (BPH) and carcinoma of the prostate (CAP) by measuring free (F), complexed (C) and total concentrations (T) of prostate specific antigen (PSA). J Urol. 151:1994;400A.
37. Marley GM, Miller MC, Kattan MW, Zhao G, Patton KP, Vessella RL. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology. 48:1996;6-6.
38. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol. 159:1998;1238-1242.
39. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc. 279:1998;1542-1547.
40. Zhang W-M, Finne P, Leinonen J, Stenman U-H. Assay of prostate-specific antigenthe complexed with alpha-1-protease inhibitor in serum (Abstr. ) Scand J Clin Lab Invest. 58:1988;228-215.
41. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem. 39:1993;2483-2491.
42. Zhang W-M, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman U-H. Characterization and immunological determination of the complex between prostate-specific antigen and alpha-2-macroglobulin. Clin Chem. 4:1998;2471-2479.
43. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun. 161:1989;1151-1159.
44. Riegman PH, Vlietstra RJ, van der Korput J, Romijn JC, Trapman J. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun. 159:1989;95-102.
45. Kumar A, Goel AS, Hill TM, Mikolajczyk SD, Millar LS, Kuus RK, Saedi MS. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res. 56:1996;5397-5402.
46. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun. 238:1997;549-555.
47. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem. 272:1997;21582-21588.
48. Piironen T, Villoutreix BO, Becker C, Hollingsworth K, Vihinen M, Bridon D. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling [In Process Citation]. Protein Sci. 7:1998;259-269.
49. Stamey T, Prestigiacomo A, Chen Z. Standardization of immunoassays for prostate specific antigen: a different view based on experimental observations. Cancer. 74:1994;1662-1666.
50. Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FHJ. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology. 1996;23-32.
51. Franks L. Latent carcinoma of the prostate. J Path Bact. 68:1954;603-616.
52. Sakr W, Grignon D, Haas G, Heilbrun J, Crissman J, Pones J. Pathology of prostate cancer and premalignant lesions in African-American and caucasian men: an epidemiologic and morphologic study. Cockett A, Aso Y, Chatelain C. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia. 1996;389-400 Scientific Communication Int.
53. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 344:1994;1594-1598.
54. Schmid HP, McNeal JE, Stamey TA. Clinical observations on the doubling time of prostate cancer. Eur Urol. 2:1993;60-63.
55. Brendler CB. Characteristics of prostate cancer found with early detection regimens. Urology. 1995;71-76.
56. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 52:1992;3323-3328.
57. Stamey TA, Graves HC, Wehner N, Ferrari M, Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol. 149:1993;787-792.
58. Yu, H, Diamandis, EP, Wong, PY, Nam, R, Trachtenberg, J, 1997, Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.
59. Stamey TA, Kabalin JN, Ferrari M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol. 141:1989;1084-1087.
60. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 141:1989;1088-1090.
61. Henttu P, Liao SS, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology. 130:1992;766-772.
62. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 21:1992;63-73.
63. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status. J Urol. 145:1991;802-806.
64. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1991;1156-1161.
65. Catalona W, Hudson M, Scardino P, Richie J, Ahmann F, Flanigan R. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristics curves. J Urol. 152:1994;2037-2042.
66. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 147:1992;846-851.
67. Catalona, WJ, Smith, DS, Ornstein, DK, 1997, Prostate cancer detection in men with serum PSA concentrations of 2, 6, 4.
68. Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, Hugosson J. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng. /ml. Prostate specific antigen [see comments]. J Urol. 159:1998;899-903.
69. Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology. 1996;45-50.
70. Rodriguez-Rubio F, Robles JE, Gonzalez A, Arocena J, Sanz G, Diez CF. Effect of digital rectal examination and flexible cystoscopy on free and total prostate-specific antigen, and the percentage of free prostate-specific antigen. Differences between two PSA assays [In Process Citation]. Eur Urol. 33:1998;255-260.
71. Babaian RJ, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal. 4:1990;135-137.
72. Oesterling J, Jacobsen S, Klee G, Pettersson K, Piironen T, Stemnan U-H. Free, complexed, and total serum PSA: establishment of age-specific reference ranges using newly developed immunofluorometric assays (IFMA). J Urol. 151:1994;311A.
73. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J Am Med Assoc. 269:1993;57-60.
74. Arcangeli CG, Humphrey PA, Smith DS, Harmon TJ, Shepherd DL, Keetch DW, Catalona WJ. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology. 51:1998;558-564.
75. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 143:1990;747-752.
76. Tarle M, Kraljic I. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Anticancer Res. 17:1997;1531-1534.
77. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992.
78. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction [see comments]. J Urol. 157:1997;1315-1321.
79. Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, Carter HB. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology. 48:1996;6.
80. Harris, CH, Dalkin, BL, Martin, E, Marx, PC, Ahmann, FR, 1997, Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.
81. Prestigiacomo, AF, Stamey, TA, 1996, Physiological variation of serum prostate specific antigen in the 4.
82. Nixon RG, Lilly JD, Liedtke RJ, Batjer JD. Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen. Arch Pathol Lab Med. 121:1997;385-391.
83. Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WL. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers [see comments]. J Urol. 157:1997;2179-2182.
84. Herschman JD, Smith DS, Catalona WL. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 50:1997;239-243.
85. Collins GN, Martin PJ, Wynn DA, Brooman PJ, O'Reilly PH. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice [In Process Citation]. J Urol. 157:1997;1744-1747.
86. Ornstein DK, Rao GS, Smith DS, Ratliff TL, Basler JW, Catalona WJ. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol. 157:1997;195-198.
87. Piironen T, Pettersson K, Suonpää M, Stenman UH, Oesterling JE, Lövgren T, Lilja H. In vitro , stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology. 48:1996;6-1.
88. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology. 48:1996;6-3.
89. Keetch DW, Andriole GL, Ratliff TL, Catalona WJ. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology. 50:1997;901-905.
90. Stenman U-H. Effect of long term treatment with finasteride on free and total PSA in serum (Abstract). J Urol. 155:1996;698A.
91. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. Free and total prostate-specific antigen in a screened population. Br J Urol. 79:1997;756-762.
92. Finne P, Zhang W-M, Leinonen J, Stenman U-H. The diagnostic accuracy of PSA determinations by logistic regression analysis (Abstract). Scand J Clin Lab Invest. 58:1998;228-205.
93. Gomari M, Järvi T, Hugosson J, Finne P, Stenman U-H. Learning vector quantization, multilayer perceptron, neurofuzzy network and logistic regression in the diagnosis of prostate cancer. Arabnia H. Proceedings of the 1998 International Conference on Parallel and Distributed Processing Techniques and Applications. 1998;516-525 CSREA Press, Las Vegas.